RxDoctor Payments Data

Daniel Garcia

Family · Houston, TXNPI 1578910220

Payments from drug & device makers

$804in general payments, 2019–2025

Across 40 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$539
  • Novo Nordisk$93
  • AstraZeneca$44
  • Merck$33
  • Exact Sciences$27
  • Boehringer Ingelheim$21
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$804 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$8,555
Medicare patients
67
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$88,533
JardianceEmpagliflozin24$39,739
EliquisApixaban23$25,187
FarxigaDapagliflozin Propanediol15$14,356
Tresiba Flextouch U-100Insulin Degludec14$6,437
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med58$3,505
Atorvastatin Calcium250$2,342
Rosuvastatin Calcium59$1,286
Montelukast Sodium43$865
Losartan Potassium78$834
Gabapentin46$782
Metformin Hcl115$738
Metoprolol Succinate81$731
Pantoprazole Sodium61$719
Vitamin D2Ergocalciferol (Vitamin D2)51$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$88,53345 claims
Boehringer IngelheimJardiance$21$39,73924 claims
PfizerEliquis$18$25,18723 claims
AstraZenecaFarxiga$44$14,35615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →